P2-IMU-838-PMS – Patients with Progressive Multiple Sclerosis

P2-IMU-838-PMS

$

This study evaluates the safety, effectiveness and tolerability of IMU-838 in patients with Progressive Multiple Sclerosis

$

This trial will accept new patients soon.

$

The purpose of this study is to find out if an investigational new drug called IMU-838 may slow down your disease progression; however, such a benefit is not yet known in PPMS or SPMS and to see if the drug is safe to be administered in people.

$

Basic Enrollment Criteria:

  • Age 18-65 years old, Male & Female
  • Willing to comply with study visits and requirements
$

Study Length:

  • 72-120 weeks for Main Study treatment period

Participate In This Study

Sign-up Here